Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results

Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results

THE WOODLANDS, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc.^® (Nasdaq:RPRX) today announced financial results for the first quarter
ended March 31, 2013.

Liquidity and Capital Resources

The Company had cash and cash equivalents of approximately $17.2 million as of
March 31, 2013 as compared to $24.2 million as of December 31, 2012. Net cash
of approximately $6.8 million was used in operating activities during the
three month period ended March 31, 2013 as compared to $2.5 million for the
same period in the prior year. The major use of cash during the three month
period ended March 31, 2013 was to fund the Company's clinical development
programs and associated administrative costs. Cash used in investing
activities during the three month period ended March 31, 2013 was
approximately $300,000 primarily for capitalized patent and patent application
costs for Androxal^® and Proellex^®. 

Financial Results

Net loss for the three month period ended March 31, 2013, was ($7.4) million,
or ($0.41) per share, as compared to a net loss of ($2.4) million, or ($0.17)
per share, for the same period in 2012.The increase in loss for the three
month period ended March 31, 2013 as compared to the same period in 2012 was
primarily due to an increase in clinical development expenses related to
Androxal due to the ongoing Phase 3 studies in men with secondary
hypogonadism, including two pivotal studies being conducted under a Special
Protocol Assessment, a six month open label safety study and a one year DEXA
study.

Research and development ("R&D") expenses increased 330%, or approximately
$4.8 million, to $6.3 million for the three month period ended March 31, 2013
as compared to $1.5 million for the same period in the prior year.The
increase in R&D expenses is primarily due to the $4.5 million increase in
clinical development expenses for Androxal®.R&D expenses related to the
clinical development of Proellex® decreased approximately $27,000, due to the
winding down of our Phase 2 vaginal administration study for uterine fibroids,
partially offset by an increase in expenses related the Phase 2 endometriosis
study initiated in the fourth quarter of 2012.Payroll and benefits expenses
increased for the three month period ended March 31, 2013 as compared to the
same period in the prior year by $350,000 due to increased headcount and
non-cash stock based compensation. Additionally, operating and occupancy
expenses remained relatively constant at $348,000 for the three month period
ended March 31, 2013.

General and administrative ("G&A") expenses increased 10%, or approximately
$94,000, to approximately $1.1 million for the three month period ended March
31, 2013 as compared to $973,000 for the same period in the prior year.The
increase in G&A expenses for the three month period ended March 31, 2013 as
compared to the same period in the prior year is primarily due to an increase
in professional services.

As of March 31, 2013, the Company had 18,643,986 shares of common stock
outstanding.

About Repros Therapeutics Inc. ^ ®

Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including the ability to raise additional needed capital on a
timely basis in order for it to continue to fund development of its Androxal®
and Proellex® programs and have success in the clinical development of its
technologies, the reliability of interim results to predict final study
outcomes, and such other risks which are identified in the Company's most
recent Annual Report on Form 10-K and in any subsequent quarterly reports on
Form 10-Q. These documents are available on request from Repros Therapeutics
or at www.sec.gov. Repros disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

For more information, please visit the Company's website at
http://www.reprosrx.com.

REPROS THERAPEUTICS INC. AND SUBSIDIARY
(A Development Stage Company)
                                                                
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited and in thousands except per share amounts)
                                                                
                                                      Three Months Ended
                                                       March 31,
                                                      2013       2012
                                                                
                                                                
Revenues and other income                              $1       $--
                                                                
Expenses                                                         
Research and development                               6,308     1,466
General and administrative                             1,067     973
Total expenses                                         7,375     2,439
                                                                
Net loss                                               $(7,374) $(2,439)
                                                                
Net loss per share - basic and diluted                 $(0.41)  $(0.17)
                                                                
Weighted average shares used in loss per share                   
calculation:
Basic                                                  18,182    13,983
Diluted                                                18,182    13,983
                                                                
CONSOLIDATED BALANCE SHEETS
(unaudited and in thousands)
                                                                
                                                      March 31,  December 31,
                                                       2013       2012
                                                                
                                                                
Cash and cash equivalents                              $17,150  $24,212
Prepaid expenses and other currents assets             355       406
Fixed assets (net)                                     90        53
Patents (net)                                          2,320     2,161
Total assets                                           $19,915  $26,832
                                                                
Accounts payable and accrued expenses                 $3,626   $3,798
Stockholders' equity                                   16,289    23,034
Total liabilities and stockholders' equity             $19,915  $26,832

CONTACT: Joseph S. Podolski
         Chief Executive Officer
         (281) 719-3447
        
         Investor Relations: Thomas Hoffmann
         The Trout Group
         (646) 378-2931

company logo
 
Press spacebar to pause and continue. Press esc to stop.